Sustained-Release Injectable Drug Delivery - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Sustained-Release Injectable Drug Delivery
A review on the current status of long-acting injectables, including commercially marketed products. This article is part of a special Drug Delivery issue.


Pharmaceutical Technology
pp. s6-s13

31. C. Dai, B. Wang, and H. Zhao, Colloids Surf. B Biointerfaces 41 (2–3), 117–20 (2005).

32. M. Shameem, H. Lee, and P.P. DeLuca, AAPS PharmSci 1 (3), E7 (1999).

33. K.W. Burton et al., J. Biomater. Sci. Polym. Ed. 11 (7), 715–729 (2000).

34. J.W. Kostanski, AAPS PharmSciTech 1 (4), E27 (2000).

35. J.W. Kostanski, B.C. Thanoo, and P.P. DeLuca, Pharm. Dev. Technol. 5 (4), 585–596 (2000).

36. H.B. Ravivarapu, K. Burton, and P.P. DeLuca, Eur. J. Pharm. Biopharm. 50 (2), 263–270 (2000).

37. B.H. Woo, Pharm. Res. 18 (11), 1600–1606 (2001).

38. G. Jiang et al., J. Control. Release 79 (1–3), 137–145 (2002).

39. A. Karatas et al. J. Microencapsul. 26 (1), 63–74 (2009).

40. L. Sun et al. J. Mater. Sci. Mater. Med. 20 (10), 2035–2042 (2009).

41. J.S. Deng, Pharm. Dev. Technol. 8 (1), 31–38 (2003).

42. H. Gao et al., World J. Gastroenterol. 10 (14), 2010–2013 (2004).

43. C. Lherm, Int. J. Pharm. 84 (1), 13–22 (1992).

44. X.J. Loh, S.H. Goh, and J. Li, Biomacromolecules 8 (2), 585–593 (2007).

45. N. Bhattarai et al., J. Control. Release 103 (3), 609–624 (2005).

46. Y. Zhai et al., J. Biomater. Sci. Polym. Ed. 20 (7–8), 923–934 (2009).

47. C.B. Liu et al. J. Biomed. Mater. Res. Part B Appl. Biomater. 84B (1), 165–175 (2008).

48. S. Chen et al., Int. J. Pharm. 288 (2), 207–218 (2005).

49. M.A. Royals et al. J. Biomed. Mater. Res. 45 (3), 231–239 (1999).

50. A.C. Altamura et al., Drugs 63 (5), 493–512 (2003).

51. E.D. Knox and G.L. Stimmel, Clin. Ther. 26 (12), 1994–2002 (2004).

52. J.P. Kelleher et al. , CNS Drugs 16 (4), 249–261 (2002).

53. M.N. Samtani, A. Vermeulen, and K. Stuyckens, Clin. Pharmacokinet. 48 (9), 585–600 (2009).

54. D. Hough et al., Schizophr. Res. 116 (2–3), 107–117 (2010).

55. M. Kramer et al., Int. J. Neuropsychopharmacol. 13 (5), 635–647 (2010).

56. H.A. Nasrallah et al., Neuropsychopharmacology 35 (10), 2072–2082 (2010).

57. H. Ascher-Svanum et al., Eur. Psychiatry, in press (2010).

58. J. Lindenmayer, Neuropsychiatr. Dis. Treat. 6 , 261–267 (2010).

59. D.P. McDonnell et al., BMC Psychiatry 10, 45 (2010).

60. L. Citrome, Patient Prefer Adherence 3, 345–355 (2009).

61. H. Okada, Adv. Drug. Deliv. Rev. 28 (1), 43–70 (1997).

62. J.D. Croxtall and L.J. Scott, Drugs 68 (5), 711–723 (2008).

63. F.W. Okumu et al., Biomaterials 23 (22), 4353–4358 (2002).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
10%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
8%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
Source: Pharmaceutical Technology,
Click here